Intellia Therapeutics (38I) Price & Analysis

Compare

14 Followers

38I Stock Chart & Stats

€11.76

-€0.50(-4.02%)

At close: Jan 08 4:00 PM EST

€11.76

-€0.50(-4.02%)

Day’s Range― - ―

52-Week Range€5.30 - €24.34

Previous CloseN/A

Volume0.00

Average Volume (3M)1.33K

Market Cap

$1.26B

Enterprise ValueN/A

Total Cash (Recent Filing)$511.04M

Total Debt (Recent Filing)$97.97M

Price to Earnings (P/E)―

Beta1.49

Next Earnings

Feb 19, 2026

EPS Estimate

-0.85

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.80

Shares Outstanding107,346,886

10 Day Avg. Volume2,015

30 Day Avg. Volume1,329

Financial Highlights & Ratios

PEG Ratio0.71

Price to Book (P/B)1.32

Price to Sales (P/S)19.91

P/FCF Ratio-3.25

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$18.94

Price Target Upside61.04% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering21

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessEfficacy data for nex-z has looked impressive, with durable reductions in TTR and functional benefits noted in the phase 1 trial.

Financial ValuationUsing an 11% discount rate and 3% terminal growth rate, our discounted cash flow (DCF)-based analysis has resulted in an estimated EV of ~$2B.

Market PotentialATTR-CM diagnosis has surged ~7X between 2016 and 2025 at Dr. Garcia's center, pointing to a growing addressable population.

Bears Say

Regulatory ChallengesThe FDA placed a formal clinical hold on the Phase III ATTR studies following safety concerns, causing a pause in enrollment.

Safety ConcernsThe patient who experienced the grade 4 liver safety event passed away, complicating the path to market.

Stock PerformanceIntellia shares are trading down over 20% aftermarket in response to news the ATTR-CM patient dosed with nex-z who was hospitalized with abdominal pain and triggered Hy’s law has died.

Intellia Therapeutics News

Cathie Wood Sells Tesla (TSLA) Stock, and Buys This Stock after Q3 Beat

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Friday, November 7, according to daily fund...

4h ago

TTD

BEAM

Midday Fly By: Musk pay plan approved, ‘GTA VI’ delayed

The major averages were broadly lower near noon, putting the biggest indices on track for a down week....

20h ago

Intellia Therapeutics price target lowered to $9 from $14 at RBC Capital

RBC Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $9 from $14 and keeps a...

21h ago

NTLA

Intellia Therapeutics price target lowered to $27 from $33 at Oppenheimer

Oppenheimer lowered the firm’s price target on Intellia Therapeutics (NTLA) to $27 from $33 and keeps an Outperform...

23h ago

NTLA

Intellia: Patient who experienced Grade 4 liver safety event has passed away

Intellia provided an update on the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nexiguran ziclumeran. “We were...

23h ago

NTLA

Intellia Therapeutics reports Q3 EPS (92c) vs. ($1.34) last year

Reports Q3 revenue $13.78M vs. $9.11M last year. The company’s cash, cash equivalents and marketable securities as of...

23h ago

NTLA

Intellia Therapeutics price target lowered to $4 from $9 at Baird

Baird lowered the firm’s price target on Intellia Therapeutics (NTLA) to $4 from $9 and keeps a Neutral...

1d ago

NTLA

Intellia Therapeutics price target lowered to $12 from $17 at Wells Fargo

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $12 from $17 and keeps an...

1d ago

NTLA

Intellia Therapeutics price target lowered to $21 from $29 at Citizens JMP

Citizens JMP lowered the firm’s price target on Intellia Therapeutics (NTLA) to $21 from $29 and keeps an...

1d ago

NTLA

Intellia Therapeutics price target lowered to $14 from $24 at Barclays

Barclays analyst Gena Wang lowered the firm’s price target on Intellia Therapeutics (NTLA) to $14 from $24 and...

1d ago

NTLA

Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan

JPMorgan downgraded Intellia Therapeutics (NTLA) to Underweight from Neutral with a price target of $5, down from $12....

1d ago

NTLA

Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings

Cathie Wood’s Ark Invest has made a series of portfolio adjustments. The firm trimmed exposure to several biotech...

3d ago

TXG

CRSP

Cathie Wood Cuts Stake in Palantir Stock (PLTR) Ahead of Q3, Loads Up on Bullish (BLSH) and Intellia (NTLA)

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) revealed several key portfolio moves for Friday, October 31, 2025, continuing their recent trend...

5d ago

BLSH

KTOS

Intellia Therapeutics’ Earnings Call: Progress Amid Challenges

Intellia Therapeutics Inc (($NTLA)) has held its Q3 earnings call. Read on for the main highlights of the...

12h ago

NTLA

38I FAQ

What was Intellia Therapeutics’s price range in the past 12 months?

Intellia Therapeutics lowest stock price was €5.30 and its highest was €24.34 in the past 12 months.

What is Intellia Therapeutics’s market cap?

Intellia Therapeutics’s market cap is $1.26B.

When is Intellia Therapeutics’s upcoming earnings report date?

Intellia Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 103 days.

How were Intellia Therapeutics’s earnings last quarter?

Intellia Therapeutics released its earnings results on Nov 06, 2025. The company reported -€0.795 earnings per share for the quarter, beating the consensus estimate of -€0.869 by €0.073.

Is Intellia Therapeutics overvalued?

According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Intellia Therapeutics pay dividends?

Intellia Therapeutics does not currently pay dividends.

What is Intellia Therapeutics’s EPS estimate?

Intellia Therapeutics’s EPS estimate is -0.85.

How many shares outstanding does Intellia Therapeutics have?

Intellia Therapeutics has 107,346,886 shares outstanding.

What happened to Intellia Therapeutics’s price movement after its last earnings report?

Intellia Therapeutics reported an EPS of -€0.795 in its last earnings report, beating expectations of -€0.869. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Intellia Therapeutics?

Currently, no hedge funds are holding shares in DE:38I

Intellia Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-56.95%

Trailing 12-Months

Asset Growth

-24.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics (38I) Earnings & Revenues

Historic Earnings Reports

38I Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Negative

The earnings call presented a mix of progress and challenges. While significant advancements were made in the lonvo-z program and financial stability was maintained, the clinical hold on nex-z trials due to patient safety concerns significantly impacted the company's outlook. The sentiment is largely influenced by the serious nature of the clinical hold and patient safety issues.View all DE:38I earnings summaries

38I Revenue Breakdown

100.00% Collaboration revenue

38I Stock 12 Month Forecast

Average Price Target

€18.94

▲(61.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","26":"€26","47":"€47","15.5":"€15.5","36.5":"€36.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46.84771296,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€46.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.9386217392,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€18.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.80795216,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.81</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,15.5,26,36.5,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.485,13.282131766153846,16.079263532307692,18.87639529846154,21.673527064615385,24.47065883076923,27.267790596923078,30.064922363076924,32.86205412923077,35.65918589538462,38.45631766153846,41.25344942769231,44.050581193846156,{"y":46.84771296,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.485,11.135278595323076,11.785557190646154,12.43583578596923,13.086114381292306,13.736392976615384,14.38667157193846,15.036950167261537,15.687228762584613,16.33750735790769,16.98778595323077,17.638064548553846,18.288343143876922,{"y":18.9386217392,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.485,10.279073243076922,10.073146486153846,9.867219729230769,9.661292972307692,9.455366215384615,9.249439458461538,9.04351270153846,8.837585944615384,8.631659187692307,8.42573243076923,8.219805673846153,8.013878916923076,{"y":7.80795216,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.525,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.06,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.952,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.234,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.522,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.752,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.384,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.485,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >